MA44209A - Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate - Google Patents

Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Info

Publication number: MA44209A
Authority: MA; Morocco
Prior art keywords: phosphorodiamidate oligomer; phosphorodiamidate; oligomer; pure; preparing
Prior art date: 2015-08-05

Application number

MA044209A

Other languages

English (en)

Other versions

MA44209B1 (fr

Inventor

Hyeong Wook Choi

Atsushi Endo

Francis Fang

Mingde Shan

Robert T Yu

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-05

Filing date

2016-08-05

Publication date

2021-04-28

2016-08-05 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2021-04-28 Publication of MA44209A publication Critical patent/MA44209A/fr

2022-03-31 Publication of MA44209B1 publication Critical patent/MA44209B1/fr

Links

ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 title 3
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000008569 process Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA44209A 2015-08-05 2016-08-05 Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate MA44209B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562201510P	2015-08-05	2015-08-05
PCT/US2016/045876 WO2017024264A2 (fr)	2015-08-05	2016-08-05	Réactifs chiraux pour la préparation d'oligomères homogènes

Publications (2)

Publication Number	Publication Date
MA44209A true MA44209A (fr)	2021-04-28
MA44209B1 MA44209B1 (fr)	2022-03-31

Family

ID=56943909

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA44209A MA44209B1 (fr)	2015-08-05	2016-08-05	Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Country Status (31)

Country	Link
US (4)	US10457698B2 (fr)
EP (2)	EP4039690B1 (fr)
JP (4)	JP6978406B2 (fr)
KR (2)	KR20250005537A (fr)
CN (3)	CN108350005B (fr)
AU (3)	AU2016302009B2 (fr)
CA (1)	CA2994842A1 (fr)
CL (1)	CL2018000322A1 (fr)
CO (1)	CO2018001615A2 (fr)
CY (1)	CY1125552T1 (fr)
DK (1)	DK3331891T3 (fr)
ES (2)	ES2907629T3 (fr)
HR (1)	HRP20220129T1 (fr)
HU (2)	HUE067910T2 (fr)
IL (3)	IL293066A (fr)
LT (1)	LT3331891T (fr)
MA (1)	MA44209B1 (fr)
MD (1)	MD3331891T2 (fr)
MX (2)	MX389022B (fr)
MY (1)	MY196627A (fr)
NZ (2)	NZ778825A (fr)
PE (2)	PE20231843A1 (fr)
PH (1)	PH12018500265A1 (fr)
PL (1)	PL3331891T3 (fr)
PT (1)	PT3331891T (fr)
RS (1)	RS62930B1 (fr)
SI (1)	SI3331891T1 (fr)
SM (1)	SMT202200089T1 (fr)
UA (1)	UA123995C2 (fr)
WO (1)	WO2017024264A2 (fr)
ZA (3)	ZA201801518B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017024264A2 (fr) *	2015-08-05	2017-02-09	Eisai R&D Management Co., Ltd.	Réactifs chiraux pour la préparation d'oligomères homogènes
CN109937042B (zh) *	2016-09-20	2023-06-27	科罗拉多州立大学董事会法人团体	使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
AU2020411964A1 (en)	2019-12-26	2022-06-16	National Center Of Neurology And Psychiatry	Antisense nucleic acid that induces skipping of exon 50
PE20230237A1 (es)	2020-02-28	2023-02-07	Nippon Shinyaku Co Ltd	Acidos nucleicos antisentido que inducen la omision del exon 51
AR124302A1 (es)	2020-12-11	2023-03-15	Eisai R&D Man Co Ltd	Gápmeros de oligonucleótidos de objetivo tau
EP4259798A1 (fr)	2020-12-11	2023-10-18	Eisai R&D Management Co., Ltd.	Gapmères de poly-morpholino oligonucléotides
IL307787A (en)	2021-04-28	2023-12-01	Eisai R&D Man Co Ltd	ANTISENSE OLIGONUCLEOTIDES and their use for the treatment of neurodegenerative disorders
CN119816508A (zh) *	2022-07-07	2025-04-11	卫材R&D管理有限公司	用于制备反义寡核苷酸的结晶单体及其制备方法和用途
WO2024092256A2 (fr)	2022-10-27	2024-05-02	Eisai R&D Management Co., Ltd.	Oligonucléotides antisens-peptides et leur utilisation pour le traitement de troubles neurodégénératifs
WO2024163762A2 (fr) *	2023-02-01	2024-08-08	Alnylam Pharmaceuticals, Inc.	Cycle à six chaînons contenant des oligomères

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5185444A (en) *	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US6117993A (en) *	1995-05-23	2000-09-12	Hybridon, Inc.	Synthons for oligonucleotide synthesis
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5874554A (en) *	1996-12-13	1999-02-23	Incyte Pharmaceuticals, Inc.	Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
US6306599B1 (en)	1999-07-16	2001-10-23	Agilent Technologies Inc.	Biopolymer arrays and their fabrication
EP1176151B1 (fr) *	2000-07-28	2014-08-20	Agilent Technologies, Inc.	Synthèse des polynucléotides utilisant la chimie combinée d'oxidation et de protection
AR036122A1 (es)	2001-07-03	2004-08-11	Avecia Biotechnology Inc	Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
CA2884340C (fr) *	2007-11-15	2017-07-25	Sarepta Therapeutics, Inc.	Procede de synthese d'oligomeres morpholino
US8076476B2 (en)	2007-11-15	2011-12-13	Avi Biopharma, Inc.	Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US9914745B2 (en)	2009-08-14	2018-03-13	Indian Association For The Cultivation Of Science	Morpholino-based antisense agent
JP2013530154A (ja) *	2010-05-28	2013-07-25	サレプタセラピューティクス，インコーポレイテッド	修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
PL2623507T3 (pl) *	2010-09-30	2017-03-31	Nippon Shinyaku Co., Ltd.	Pochodna kwasu morfolinonukleinowego
US9161948B2 (en) *	2011-05-05	2015-10-20	Sarepta Therapeutics, Inc.	Peptide oligonucleotide conjugates
WO2012150960A1 (fr) *	2011-05-05	2012-11-08	Avi Biopharma, Inc.	Conjugués peptides/oligonucléotides
AR088109A1 (es)	2014-04-11	2014-05-07	Gilead Sciences Inc	Metodo para preparar analogos nucleotidicos antivirales
BR112014011875B1 (pt)	2011-11-18	2022-01-04	Sarepta Therapeutics, Inc	Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
EP2785729B1 (fr)	2011-11-30	2020-11-04	Sarepta Therapeutics, Inc.	Oligonucléotides pour le traitement de maladies à répétition étendue
CN102702265A (zh)	2012-05-14	2012-10-03	天津特安化学科技有限公司	一种固相合成磷酰二胺吗啉代寡核苷酸及方法
KR20180030917A (ko)	2015-08-05	2018-03-26	얀센 바이오테크 인코포레이티드	항-cd154 항체 및 그의 사용 방법
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017024264A2 (fr) *	2015-08-05	2017-02-09	Eisai R&D Management Co., Ltd.	Réactifs chiraux pour la préparation d'oligomères homogènes
DE102015214943A1 (de)	2015-08-05	2017-02-09	Siemens Aktiengesellschaft	Verfahren und Anlage für eine chemische Synthese

2016
- 2016-08-05 WO PCT/US2016/045876 patent/WO2017024264A2/fr not_active Ceased
- 2016-08-05 IL IL293066A patent/IL293066A/en unknown
- 2016-08-05 SI SI201631470T patent/SI3331891T1/sl unknown
- 2016-08-05 NZ NZ778825A patent/NZ778825A/en unknown
- 2016-08-05 CN CN201680058501.2A patent/CN108350005B/zh active Active
- 2016-08-05 PE PE2023000140A patent/PE20231843A1/es unknown
- 2016-08-05 UA UAA201802109A patent/UA123995C2/uk unknown
- 2016-08-05 RS RS20220178A patent/RS62930B1/sr unknown
- 2016-08-05 HR HRP20220129TT patent/HRP20220129T1/hr unknown
- 2016-08-05 SM SM20220089T patent/SMT202200089T1/it unknown
- 2016-08-05 MX MX2018001557A patent/MX389022B/es unknown
- 2016-08-05 MA MA44209A patent/MA44209B1/fr unknown
- 2016-08-05 CA CA2994842A patent/CA2994842A1/fr active Pending
- 2016-08-05 HU HUE21210674A patent/HUE067910T2/hu unknown
- 2016-08-05 KR KR1020247042650A patent/KR20250005537A/ko active Pending
- 2016-08-05 DK DK16767053.8T patent/DK3331891T3/da active
- 2016-08-05 HU HUE16767053A patent/HUE057593T2/hu unknown
- 2016-08-05 KR KR1020187006255A patent/KR102788397B1/ko active Active
- 2016-08-05 ES ES16767053T patent/ES2907629T3/es active Active
- 2016-08-05 AU AU2016302009A patent/AU2016302009B2/en active Active
- 2016-08-05 JP JP2018506149A patent/JP6978406B2/ja active Active
- 2016-08-05 EP EP21210674.4A patent/EP4039690B1/fr active Active
- 2016-08-05 MD MDE20180593T patent/MD3331891T2/ro unknown
- 2016-08-05 NZ NZ778828A patent/NZ778828A/en unknown
- 2016-08-05 US US15/750,087 patent/US10457698B2/en active Active
- 2016-08-05 IL IL284611A patent/IL284611B2/en unknown
- 2016-08-05 CN CN202110735306.1A patent/CN113461733A/zh active Pending
- 2016-08-05 PE PE2018000192A patent/PE20180687A1/es unknown
- 2016-08-05 PT PT167670538T patent/PT3331891T/pt unknown
- 2016-08-05 PL PL16767053T patent/PL3331891T3/pl unknown
- 2016-08-05 LT LTEPPCT/US2016/045876T patent/LT3331891T/lt unknown
- 2016-08-05 CN CN202410065464.4A patent/CN117924364A/zh active Pending
- 2016-08-05 EP EP16767053.8A patent/EP3331891B1/fr active Active
- 2016-08-05 ES ES21210674T patent/ES2993126T3/es active Active
- 2016-08-25 MY MYPI2018000173A patent/MY196627A/en unknown
2018
- 2018-02-05 IL IL257353A patent/IL257353B2/en unknown
- 2018-02-05 CL CL2018000322A patent/CL2018000322A1/es unknown
- 2018-02-05 PH PH12018500265A patent/PH12018500265A1/en unknown
- 2018-02-06 MX MX2022000124A patent/MX2022000124A/es unknown
- 2018-02-19 CO CONC2018/0001615A patent/CO2018001615A2/es unknown
- 2018-03-05 ZA ZA2018/01518A patent/ZA201801518B/en unknown
2019
- 2019-08-15 ZA ZA2019/05394A patent/ZA201905394B/en unknown
- 2019-09-17 US US16/573,185 patent/US10836784B2/en active Active
2020
- 2020-10-28 US US17/082,070 patent/US20210171555A1/en not_active Abandoned
2021
- 2021-09-29 JP JP2021159804A patent/JP7254869B2/ja active Active
- 2021-12-21 AU AU2021290235A patent/AU2021290235B2/en active Active
2022
- 2022-01-21 ZA ZA2022/01010A patent/ZA202201010B/en unknown
- 2022-02-23 CY CY20221100159T patent/CY1125552T1/el unknown
2023
- 2023-03-29 JP JP2023053119A patent/JP7712975B2/ja active Active
- 2023-09-08 AU AU2023226763A patent/AU2023226763B2/en active Active
2024
- 2024-07-22 US US18/779,841 patent/US20250171475A1/en active Pending
2025
- 2025-03-03 JP JP2025032861A patent/JP2025090640A/ja active Pending

Also Published As

Publication number	Publication date
JP7254869B2 (ja)	2023-04-10
CY1125552T1 (el)	2024-02-16
IL284611A (en)	2021-08-31
HK1248708A1 (zh)	2018-10-19
EP4039690B1 (fr)	2024-07-17
HUE057593T2 (hu)	2022-05-28
CL2018000322A1 (es)	2018-05-18
WO2017024264A2 (fr)	2017-02-09
MX2022000124A (es)	2022-02-16
IL257353B2 (en)	2023-02-01
US20210171555A1 (en)	2021-06-10
AU2023226763B2 (en)	2025-09-18
JP2018525380A (ja)	2018-09-06
HUE067910T2 (hu)	2024-11-28
HRP20220129T1 (hr)	2022-04-15
NZ778825A (en)	2024-11-29
US10836784B2 (en)	2020-11-17
MX2018001557A (es)	2018-05-02
WO2017024264A3 (fr)	2017-03-30
RU2018107663A3 (fr)	2020-05-21
SI3331891T1 (sl)	2022-04-29
US20200115405A1 (en)	2020-04-16
AU2021290235B2 (en)	2023-06-08
US20180222932A1 (en)	2018-08-09
JP2025090640A (ja)	2025-06-17
CO2018001615A2 (es)	2018-07-19
AU2016302009B2 (en)	2021-09-30
CN108350005A (zh)	2018-07-31
EP3331891A2 (fr)	2018-06-13
US10457698B2 (en)	2019-10-29
AU2023226763A1 (en)	2023-09-28
RU2018107663A (ru)	2019-09-05
PE20231843A1 (es)	2023-11-21
PT3331891T (pt)	2022-02-28
JP6978406B2 (ja)	2021-12-08
EP4039690C0 (fr)	2024-07-17
ZA201905394B (en)	2022-07-27
IL257353B (en)	2022-10-01
PL3331891T3 (pl)	2022-03-28
IL293066A (en)	2022-07-01
RS62930B1 (sr)	2022-03-31
NZ778828A (en)	2024-11-29
SMT202200089T1 (it)	2022-03-21
CA2994842A1 (fr)	2017-02-09
BR122023025447A2 (pt)	2024-01-16
ES2993126T3 (en)	2024-12-23
JP2022003067A (ja)	2022-01-11
LT3331891T (lt)	2022-02-25
AU2021290235A1 (en)	2022-01-20
JP7712975B2 (ja)	2025-07-24
DK3331891T3 (da)	2022-02-28
MA44209B1 (fr)	2022-03-31
EP3331891B1 (fr)	2021-12-15
UA123995C2 (uk)	2021-07-07
AU2016302009A1 (en)	2018-03-29
ZA201801518B (en)	2020-10-28
IL257353A (en)	2018-04-30
JP2023085402A (ja)	2023-06-20
CN108350005B (zh)	2024-02-06
PE20180687A1 (es)	2018-04-23
US20250171475A1 (en)	2025-05-29
KR20250005537A (ko)	2025-01-09
WO2017024264A8 (fr)	2018-04-12
MX389022B (es)	2025-03-20
MD3331891T2 (ro)	2022-04-30
IL284611B1 (en)	2023-07-01
BR112018002430A2 (pt)	2018-09-18
CN113461733A (zh)	2021-10-01
ZA202201010B (en)	2024-05-30
IL284611B2 (en)	2023-11-01
CN117924364A (zh)	2024-04-26
KR102788397B1 (ko)	2025-04-01
KR20180044303A (ko)	2018-05-02
ES2907629T3 (es)	2022-04-25
PH12018500265A1 (en)	2018-08-13
MY196627A (en)	2023-04-23
EP4039690A1 (fr)	2022-08-10
NZ740490A (en)	2024-07-05

Publication	Publication Date	Title
MA44209A (fr)	2021-04-28	Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate
EP3357491A4 (fr)	2019-05-08	Composition pharmaceutique contenant un médicament anionique, et son procédé de préparation
EP3351242A4 (fr)	2019-05-15	Composition pharmaceutique orale comprenant un cannabinoïde, procédé pour sa préparation et son utilisation
ZA201808286B (en)	2021-07-28	New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MY190561A (en)	2022-04-27	New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000521A1 (en)	2019-04-12	New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en)	2019-04-12	New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
ZA201405101B (en)	2015-12-23	"new indolizine compounds, a process for their preparation and pharmaceutical compositions containing them."
TW201613859A (en)	2016-04-16	Analogs of PRIDOPIDINE, their preparation and use
MY196562A (en)	2023-04-19	New Piperidinyl Derivatives, a Process for Their Preparation and Pharmaceutical Compositions Containing Them
ZA201604976B (en)	2022-05-25	Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them
EP2742020A4 (fr)	2015-03-11	Dérivé de biguanide à substitution n1-amine cyclique-n5, procédés de préparation associés et composition pharmaceutique les comprenant
EP3398615A4 (fr)	2019-09-25	Composition pharmaceutique mucoadhésive et son procédé de préparation
EA201691741A1 (ru)	2017-02-28	Фармацевтическая композиция
EP3708173A4 (fr)	2022-03-02	COMPOSITION PHARMACEUTIQUE THÉRAPEUTIQUE POUR LE CANCER COMPRENANT UN miARN
EP2941418A4 (fr)	2016-10-26	Dérivés de biguanide à substitution n1-amine cyclique-n5, leurs procédés de préparation et composition pharmaceutique les comprenant
EP3369725A4 (fr)	2019-05-01	Sel pharmaceutique dérivé de la polyamine, son procédé de préparation et son utilisation
IL282218A (en)	2021-05-31	New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
IL267914B (en)	2022-04-01	History of monoterpene phenol, process for their preparation and pharmaceutical preparations containing them
EP2868317A4 (fr)	2015-12-30	Capsule molle de 2,2',6,6'-tétra-isopropyl-4,4'-2-bisphénol et son procédé de préparation
EP3305283A4 (fr)	2019-01-09	Composition pharmaceutique stabilisée et son procédé de préparation
PL3589622T3 (pl)	2021-10-18	Sposób przygotowywania jodku 3,7-bis(dimetyloamino)fenotiazyn-5-yliowego
EP3328435A4 (fr)	2019-03-13	Composition pharmaceutique à stabilité au stockage améliorée, et son procédé de préparation
MX2020011170A (es)	2020-11-12	Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona.
HUE053710T2 (hu)	2021-07-28	H3-ligand-tetrahidrát, eljárás elõállítására és H3-ligand-tetrahidrátot tartalmazó gyógyászati készítmények